Is early antithrombotic therapy necessary in bioprosthetic valves?

J Thorac Cardiovasc Surg. 2010 Sep;140(3):724-5; author reply 725-6. doi: 10.1016/j.jtcvs.2010.04.032.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Bioprosthesis*
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Evidence-Based Medicine
  • Fibrinolytic Agents / administration & dosage*
  • Fibrinolytic Agents / adverse effects
  • Heart Valve Diseases / surgery*
  • Heart Valve Prosthesis Implantation / adverse effects
  • Heart Valve Prosthesis Implantation / instrumentation*
  • Heart Valve Prosthesis*
  • Hemorrhage / chemically induced
  • Humans
  • Platelet Aggregation Inhibitors / therapeutic use
  • Prosthesis Design
  • Randomized Controlled Trials as Topic
  • Thromboembolism / etiology
  • Thromboembolism / prevention & control*
  • Treatment Outcome

Substances

  • Fibrinolytic Agents
  • Platelet Aggregation Inhibitors